Alexander Shinkov

Prof. Dr. Alexander Shinkov

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YDYana Danailova
Yana Danailova
Tsvetelina VelikovaTsvetelina Velikova
Tsvetelina Velikova
GNGeorgi Nikolaev
Georgi Nikolaev
ZMZorka Mitova
Zorka Mitova
ASAlexander Shinkov
Alexander Shinkov
RKRossitza Ts Konakchieva
Rossitza Ts Konakchieva
Since the thyroid gland is one of the organs most affected by autoimmune processes, many patients with thyroiditis of Hashimoto (TH) seek medical advice on lifestyle variance and dietary modifications to improve and maintain their hyroid function. In this review, we aim to present and discuss some challenges associated with the nutritional management of TH, focusing on environmental and dietary deficits, inflammatory and toxic nutrients, cyanotoxins, etc. We discuss the relationships among different diets, chronic inflammation, and microbiota, and their impact on the development and exacerbation of TH in detail. We share some novel insights into the role of vitamin D and melatonin for preserving thyroid function during chronic inflammation in autoimmune predisposed subjects. A comprehensive overview is provided on anti-inflammatory nutrients and ecological diets, including foods for cleansing and detoxification, which represent strategies to prevent relapses and achieve overall improvement of life quality. In conclusion, data from biomedical and clinical studies provide evidence that an appropriate dietary and lighting regimen could significantly improve the function of the thyroid gland and reduce the reactivity of autoantibodies in TH. Compliance with nutritional guidelines may help TH patients to reduce the need for medicines.

1 December 2003 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
GKG Kirilov
G Kirilov
ATA Tomova
A Tomova
LDL Dakovska
L Dakovska
PKP Kumanov
P Kumanov
ASAlexander Shinkov
Alexander Shinkov
AAAs Alexandrov
As Alexandrov
BACKGROUND: Recently the pathophysiological role of endothelin (ET) has been presumed in a number of adrenal disorders such as primary hyperaldosteronism, pheochromocytoma and adrenocortical insufficiency. AIM: The aim of the present study was to evaluate circulating ET-1 levels in patients with endogenous Cushing's syndrome. METHODS AND RESULTS: Plasma ET-1 levels were determined by highly sensitive RIA. Thirteen untreated subjects with Cushing's syndrome were studied: eight women and five men of mean age 44.2+/-9.5 Years (s.d.). In ten of them, Cushing's disease had been diagnosed and three had adrenal adenomas. ET-1 was 3-fold higher in the patient group than in age-matched healthy controls (n=13): 1.59+/-0.78 vs 0.46+/-0.20 pmol/l respectively, P0.05). In three patients who died of severe cardiovascular complications, plasma ET-1 was significantly higher than in the remaining patients (2.34+/-0.35 pmol/l, P<0.05). A positive correlation was found between the total cholesterol (6.94+/-1.75 mmol/l) and ET-1 levels in the patients with Cushing's syndrome: r=+0.73, P0.05. CONCLUSION: Our results clearly demonstrate that the ET system is activated in Cushing's syndrome. Elevated plasma ET-1 levels probably play a role in the pathogenesis of accelerated and early atherosclerosis development in this disorder.

5 December 2017 in Postgraduate Medicine
Verified
Journal Article
Closed access
ASAlexander Shinkov
Alexander Shinkov
ABAnna-Maria Borissova
Anna-Maria Borissova
RKRoussanka Kovatcheva
Roussanka Kovatcheva
JVJordan Vlahov
Jordan Vlahov
LDLilia Dakovska
Lilia Dakovska
PPPaulina Petkova
Paulina Petkova
Objectives: The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors associated with high cardiovascular morbidity and mortality. The MetS and its elements have been linked to anxiety and depressive disorders. The aim of the current cross-sectional study was to assess the prevalence of depression and anxiety, measured by the Zung Self-Rating Scale in subjects with and without the metabolic syndrome and diabetes. Methods: A total of 2111 adults were included, 1155 female, age 47.6 (13.7) and 956 male, age 45.2 (13.5). All participants filled questionnaires covering current and past disorders and medication, smoking and family history. Zung self-rating depression and anxiety scales were completed. Body weight, height and waist circumference were measured, BMI was calculated, serum glucose and lipids were measured. Results: Depression (SDSi) and anxiety scores (SASi) were higher in the females and increased with age (p < 0.001). SDSi was higher in the females and males with metabolic syndrome (MetS) (50.9 ± 9.8 vs. 45.9 ± 8.9, p < 0.001 and 42.7 ± 9.2 vs. 40.5 ± 7.9 p < 0.001, respectively). SASi was higher in the MetS subjects (females 50.59 ± 11.35 vs. 45.97 ± 10.58, p < 0.001; males 40.48 ± 10.1 vs. 38.04 ± 8.42, p < 0.001). Both SDSi and SASi were higher in the subjects with known diabetes than in those with normal glucose tolerance (Mann-Whitney both p < 0,001). Positive depressive scores were more prevalent in subjects with MetS than those without (females 54% vs. 31.6%, p < 0.001; males 22.7% vs. 12.3%, p < 0.001). Depression and anxiety were more prevalent in the subjects with known diabetes than in those with normal glucose tolerance but not in the newly-diagnosed diabetes. The OR for depressiveness was 2.0 (1.3; 2.6) in subjects with MetS and 4.2 (2.3; 7.8) in those with known diabetes. Conclusions: In conclusion, depressiveness and anxiety were associated positively with age and female gender and were more prevalent among subjects with MetS and known diabetes mellitus.

1 October 2010 in American Journal of Roentgenology
Verified
Journal Article
Closed access
RKRoussanka D. Kovatcheva
Roussanka D. Kovatcheva
JVJordan D. Vlahov
Jordan D. Vlahov
ASAlexander Shinkov
Alexander Shinkov
ABAnna-Maria Borissova
Anna-Maria Borissova
JHJoo Ha Hwang
Joo Ha Hwang
LHLaszlo Hegedüs
Laszlo Hegedüs
OBJECTIVE. Many patients with primary hyperparathyroidism either decline or are not candidates for surgical parathyroidectomy. There are drawbacks to medical therapy as well as percutaneous ethanol injection as alternative therapies for primary hyperparathyroidism. Therefore, in this pilot study, our aim was to test the feasibility, safety, and efficacy of a newly developed noninvasive high-intensity focused ultrasound (HIFU) technique for the nonsurgical management of primary hyperparathyroidism.SUBJECTS AND METHODS. We treated four menopausal women with biochemical, sonographic, and cytologic evidence of benign primary hyperparathyroidism. HIFU treatment was performed in two sessions using TH-One under sonographic guidance and with the patient under conscious sedation. Parathyroid volume and function were evaluated at baseline and repeatedly until 12 months after the second HIFU session.RESULTS. Serum parathyroid hormone levels decreased in all four patients and normalized 1 and 8 months after the secon...

1 August 2001 in Maturitas
Verified
Journal Article
Closed access
ABA.-M. Borissova
A.-M. Borissova
RKR. Kovatcheva
R. Kovatcheva
ASAlexander Shinkov
Alexander Shinkov
MVM. Vukov
M. Vukov

1 December 2014 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
ASAlexander Shinkov
Alexander Shinkov
ABAnna-Maria Borissova
Anna-Maria Borissova
RKRoussanka Kovatcheva
Roussanka Kovatcheva
IAIliana Atanassova
Iliana Atanassova
JVJordan Vlahov
Jordan Vlahov
LDLilia Dakovska
Lilia Dakovska
Objective The aim of the study was to assess the prevalence and characteristics of metabolic syndrome (MetS) and its elements in relation to TSH in euthyroid subjects. Materials and methods In the cross-sectional study, 2,153 euthyroid adults, 47.2 ± 14.5 years (20-94) with no current antithyroid or thyroid replacement therapy were enrolled. All participants filled a questionnaire on past and current morbidities, medication and smoking. Body weight, height, waist circumference, serum TSH, glucose and lipids were measured. The subjects were stratified by quartiles of TSH (QTSH) and the prevalence of the MetS elements was calculated. MetS was determined by the IDF 2005 criteria. Results Overweight prevalence was 37.2% (35.2-39.2), obesity in 25.1% (23.3-26.9), abdominal obesity – 61.4% (59.3-63.5), hypertension – 42.1% (38.9-43.1), diabetes/increased fasting glucose – 13.6% (12.1-15), low HDL-cholesterol – 27.6% (25.7-29.5), hypertriglyceridemia – 24.1% (22.3-25.9), MetS – 32.2% (30.2-34.2). MetS was more prevalent in the highest QTSH (34.9%, 30.9-38.9) than the lowest (27%, 23.3-30.9), p < 0.001, as were low HDL-C (32%, 28-35.9 vs. 25%, 21.3-28.7, p < 0.001) and hypertriglyceridemia (26.8%, 23-30.5 vs. 20.4%, 17-23.8, p = 0.015). Each QTSH increased the risk of MetS by 14%, p < 0.001, of hypertriglyceridemia by 20%, p = 0.001 and of low LDL-C by 9%, p = 0.042. Other significant factors for MetS were age, male gender and obesity. Conclusion The prevalence of MetS increased with higher QTSH within the euthyroid range, mostly by an increase in the dyslipidemia. Arq Bras Endocrinol Metab. 2014;58(9):926-32